All In Biotech

Drug Trial Radar · NCT07124936

A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

A Phase 1b/2 Study to Evaluate the Safety, Tolerability, and Antitumor Activity of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Aug 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

97

Planned (sponsor's estimate)

Start

Jul 30, 2025

Primary completion

Oct 26, 2027

Study completion Oct 25, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma. This study will include two arms: Cohort A (HDM2005 + R-GemOx) will enroll participants with relapsed/refractory DLBCL. Cohort B (HDM2005 + R-CHP) will enroll participants with untreated DLBCL. The study will consist of two parts: dose-escalation part and dose-expansion part.

Conditions

  • Diffuse Large B Cell Lymphoma (DLBCL)

Interventions

  • HDM2005Drug

    HDM2005 will be administered as an intravenous injection.

  • Rituximab or Rituximab biosimilarDrug

    Rituximab or Rituximab biosimilar will be administered as an intravenous injection.

  • GemcitabineDrug

    Gemcitabine will be administered as an intravenous injection.

  • OxaliplatinDrug

    Oxaliplatin will be administered as an intravenous injection.

  • CyclophosphamideDrug

    Cyclophosphamide will be administered as an intravenous injection.

  • DoxorubicinDrug

    Doxorubicin will be administered as an intravenous injection.

  • PrednisoneDrug

    Prednisone will be administered orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants who experience dose-limiting toxicities (DLTs) in dose-escalation partTime frame: Up to ~3 weeks
  2. Number of participants who experience adverse events (AEs), serious adverse events (SAEs) and adverse events of special interest (AESIs) in dose-escalation partTime frame: Up to ~54 months
  3. Complete response (CR) rate in dose-expansion partTime frame: Up to ~30 months
  4. RP2D of HDM2005Time frame: Up to ~30 months

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China · Not yet recruiting

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Not yet recruiting

  • The Affiliated Tumor Hospital of Guangxi Medical University

    Nanning, Guangxi, China · Not yet recruiting

  • Affiliated Tumor Hospital of Harbin Medical University

    Harbin, Heilongjiang, China · Not yet recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Not yet recruiting

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Not yet recruiting

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China · Not yet recruiting

  • HunanCancer Hospital

    Changsha, Hunan, China · Not yet recruiting

  • Second Affiliated Hospital of Soochow University

    Suzhou, Jiangsu, China · Not yet recruiting

  • The First Affiliated Hospital Of Nanchang University

    Nanchang, Jiangxi, China · Not yet recruiting

  • The first hospital of Jilin University

    Changchun, Jilin, China · Not yet recruiting

  • Shengjing Hospital Affiliated to China Medical University

    Shenyang, Liaoning, China · Not yet recruiting

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China · Not yet recruiting

  • Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute,Shandong Cancer Hospital)

    Jinan, Shandong, China · Not yet recruiting

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China · Not yet recruiting

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, China · Not yet recruiting

  • The Second Affiliated Hospital of Kunming Medical UniversityThe Second Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Active not recruiting

  • Yunnan Cancer Hospital

    Kunming, Yunnan, China · Not yet recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.